MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

GlobeNewsWire • Jun 23, 2026

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

GlobeNewsWire • Jun 5, 2026

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

GlobeNewsWire • Jun 3, 2026

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza's pediatric label extension as a durable growth inflection, targeting a concentrated 360,000-patient U.S. base and 30,000 annual inflow, with an efficient commercial strategy. MNKD estimates a 23–37% pediatric market share, translating to a $300–500 million revenue opportunity, with gradual adoption expected to accelerate meaningfully by 4Q26 and into 2027.

Seeking Alpha • Jun 3, 2026

MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market

MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin's label into children and adolescents.

MarketBeat • May 31, 2026

US FDA approves MannKind's inhaled insulin for children

The U.S. Food and Drug Administration has approved expanded use ​of MannKind's inhaled rapid-acting insulin ‌in children with diabetes, offering patients under 18 years of age a ​needle-free treatment option, the ​company said on Friday.

Reuters • May 29, 2026

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.

GlobeNewsWire • May 29, 2026

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

Seeking Alpha • May 29, 2026

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes

GlobeNewsWire • May 29, 2026

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS

GlobeNewsWire • May 27, 2026